Xuegang Yang. "DEB-TACE combined with apatinib and camrelizumab as second-line therapy for unresectable intrahepatic cholangiocarcinoma: A prospective, single-arm, phase II study.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.4164